Latanoprost ophthalmic Pregnancy and Breastfeeding Warnings
Latanoprost ophthalmic is also known as: Xalatan
Latanoprost ophthalmic Pregnancy Warnings
Latanoprost ophthalmic solution has been assigned to pregnancy category C by the FDA. Animal data have revealed evidence of embryotoxicity at high doses. There are no controlled data in human pregnancy. Latanoprost should only be given during pregnancy when benefit outweighs risk.
One case report described the use of latanoprost and timolol gel-forming solution during an entire pregnancy. Placental insufficiency occurred, but the infant was normal. An observational study involving 10 pregnant women receiving latanoprost ophthalmic therapy during the first trimester of pregnancy, embryo exposure ranging from 4 to 70 days, reported a lack of maternal systemic side effects, threatening abortion or preterm labor, and neonatal malformation as a consequence of latanoprost. One patient experienced an early spontaneous abortion; however, latanoprost causality was deemed unlikely. Normal neonatal and maternal outcomes were reported in 3 women who continued therapy throughout pregnancy and 1 woman who discontinued therapy during the third trimester. Despite these reports the author cautions that considering the potential systemic oxytocic effects of all prostaglandin analogs latanoprost therapy during pregnancy is not yet advisable.
Latanoprost ophthalmic Breastfeeding Warnings
There are no data on the excretion of topically administered latanoprost or its metabolites into human milk. The manufacturer recommends that caution be used when administering latanoprost to nursing women.
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.